Institutional Form 4 Intelligence

Paul Roman Capital

Insider Terminal

High-conviction filings ranked by dollar size across equities, credit, funds and option-linked activity.

Filings
11
11 buys · 0 sells
Buy Volume
$223.31M
Sell Volume
$0
Net Flow
+$223.31M
Lead GGR +$35.11M
Buy $223.31MFlow mixSell $0
ALLBUYSSELLS
$100K+$500K+$1M+$5M+$10M+$50M+
Derivatives

Options

$ rank
Showing
11
Perf 11/11
GGR
Gogoro Inc.
Yin Chung-YaoF28
DirectorT+2
+$35.11M
−9.7%
α −4.3%
BUYOct 7
ADRX
Adarx Pharmaceuticals
Sr One Capital Management, LlcF24
Major HolderT+1
+$27.20M
−34.1%
α −30.2%
BUYSep 28
ADRX
Adarx Pharmaceuticals
George SimeonF24
Major HolderT+1
+$27.20M
−34.1%
α −30.2%
BUYSep 28
ETRA
Electra Therapeutics
Gordon Carl LF28
Major HolderT+2
+$20.00M
−44.0%
α −39.0%
BUYSep 21
ETRA
Electra Therapeutics
Orbimed Advisors LlcF28
Major HolderT+2
+$20.00M
−44.0%
α −39.0%
BUYSep 21
ASPE
Aspen Neuroscience
Arch Venture Fund X, L.P.F32
Major HolderT+0
+$20.00M
−4.6%
α −2.4%
BUYNov 2
ADRX
Adarx Pharmaceuticals
Orbimed Advisors LlcF18
Major HolderT+2
+$16.15M
−34.1%
α −30.2%
BUYSep 28
ADRX
Adarx Pharmaceuticals
Gordon Carl LF18
Major HolderT+2
+$16.15M
−34.1%
α −30.2%
BUYSep 28
ASPE
Aspen Neuroscience
Thompson Peter A.F32
Major HolderT+2
+$15.00M
−4.6%
α −2.4%
BUYNov 2
ASPE
Aspen Neuroscience
Orbimed Advisors LlcF32
Major HolderT+2
+$15.00M
−4.6%
α −2.4%
BUYNov 2
IAM
Iambic Therapeutics
Rachlin Evan LockwoodF24
DirectorT+3
+$11.50M
−57.3%
α −53.6%
BUYOct 16